The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review

Dermatol Online J. 2004 Jul 15;10(1):3.

Abstract

Tacrolimus ointment and pimecrolimus cream are approved in the United States for treatment of atopic dermatitis. Tacrolimus and pimecrolimus are both calcineurin inhibitors and function as immunosuppressants. Their mechanisms have been discussed elsewhere. This article will discuss their utility in treating psoriasis.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Calcineurin Inhibitors
  • Chemistry, Pharmaceutical
  • Double-Blind Method
  • Drug Evaluation, Preclinical
  • Facial Dermatoses / drug therapy
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / pharmacokinetics
  • Immunosuppressive Agents / therapeutic use*
  • Liposomes
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Middle Aged
  • Occlusive Dressings
  • Ointments
  • Psoriasis / drug therapy*
  • Randomized Controlled Trials as Topic
  • Skin Absorption
  • Tacrolimus / administration & dosage
  • Tacrolimus / analogs & derivatives*
  • Tacrolimus / pharmacokinetics
  • Tacrolimus / therapeutic use*
  • Treatment Outcome

Substances

  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Liposomes
  • Ointments
  • pimecrolimus
  • Tacrolimus